Bunazosin

Summary

Bunazosin (CHEMBL188185) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 373.4 Da · C19H27N5O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL188185
Name	Bunazosin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	2472
Molecular formula	C19H27N5O3
Molecular weight	373.4
InChIKey	RHLJLALHBZGAFM-UHFFFAOYSA-N

SMILES: CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC

IUPAC name: 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one

Also known as: Bunazosin, Bunazosina, Bunazosine, BUNAZOSIN, bunazosin, Bunazosin Hydrochloride

Parent form; salt/anhydrous children: CHEMBL3182014

Patent coverage: 1,093 distinct patent families (4,112 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 4,062 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Adrenergic receptor alpha-1, D(3) dopamine receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA1D	8.91	IC50	1.22	nM	CHEMBL_ACT_24959138
ADRA2C	6.26	AC50	550	nM	CHEMBL_ACT_25147514
ADRA2B	5.77	AC50	1700	nM	CHEMBL_ACT_25143349
KCNH2	5.35	AC50	4500	nM	CHEMBL_ACT_25117326

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00130156	PHASE4	COMPLETED	Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).